Charles O'Bryan-Tear

Charles O'Bryan-Tear

Net worth: 215 961 $ as of 31/03/2024

69 year
Health Technology
Consumer Services
Commercial Services

Profile

Charles Gillies O'Bryan-Tear worked as a Medical Director at Bristol-Myers Squibb Pharmaceuticals Ltd., Director at Affibody AB, Interim Medical Director at Genzyme Therapeutics Ltd., Vice President-Research & Development at GlaxoSmithKline Biologicals NV, Chief Medical Officer at Algeta ASA, and Chief Medical Officer at Scancell Holdings Plc.
He holds a doctorate from the University of Cambridge and an MBA from Cranfield University.

Known holdings in public companies

CompanyDateNumber of sharesValuationValuation date
30/06/2023 120,373 ( 0.04% ) 215 961 $ 31/03/2024

Former positions of Charles O'Bryan-Tear

CompaniesPositionEnd
CLARITY PHARMACEUTICALS LTD Director/Board Member 15/05/2023
SCANCELL HOLDINGS PLC Chief Tech/Sci/R&D Officer -
Corporate Officer/Principal -
Corporate Officer/Principal -
ALGETA ASA Chief Tech/Sci/R&D Officer -
See the detail of Charles O'Bryan-Tear's experience

Training of Charles O'Bryan-Tear

University of Cambridge Doctorate Degree
Cranfield University Masters Business Admin

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Charles O'Bryan-Tear's experience

Linked companies

Listed companies2
SCANCELL HOLDINGS PLC

Health Technology

CLARITY PHARMACEUTICALS LTD

Health Technology

Private companies5

Health Technology

Commercial Services

Health Technology

Health Technology

Health Technology

  1. Stock Market
  2. Insiders
  3. Charles O'Bryan-Tear